GEPIN

(Ranitidine)

Tablet, Syrup & Injection

Presentation

Gepin Tablet: Each film coated tablet contains Ranitidine 150 mg (as Ranitidine Hydrochloride USP).
Gepin Syrup 100 ml : Each 5 ml syrup contains Ranitidine 75 mg (as Ranitidine Hydrochloride USP).
Gepin Syrup 200 ml : Each 5 ml syrup contains Ranitidine 75 mg (as Ranitidine Hydrochloride USP).
Gepin IM/IV Injection: Each ampoule contains 2 ml sterile solution of Ranitidine 50 mg (as Ranitidine Hydrochloride USP) for IM/IV injection.

Properties and effects

Gepin is a histamine H_2-receptor antagonist with anti-ulcerant activity.

Indications

It is used in

- ▲ Gastric & Duodenal Ulcer
- ▲ Gastro Esophageal Reflux Disease
- ▲ Zollinger-Ellison Syndrome
- ▲ Erosive Oesophagitis
- ▲ Pathological Hypersecretory Conditions
- ▲ Chronic Episodic Dyspepsia
- ▲ NSAIDs Ulcer

Dosage and Administration

Gepin Tablet & Syrup

The usual dosage is 1 tab or 10 ml syrup twice daily, taken morning and evening. Alternatively, patients with duodenal ulceration, gastric ulceration or reflux oesophagitis may be treated with a single bedtime dose of 2 tablets or 20 ml syrup. In Zollinger-Ellison syndrome : Initially 1 tab or 10 ml syrup 2 time daily with a gradual increment upto 6 grams per day in divided doses. In chronic episodic dyspepsia : 1 tab or 10 ml syrup 2 times daily for six weeks.

Gepin Injection

Adults

Intramascular Injection: 50 mg (2 ml) every 6 to 8 hours.

Intermittent Intravenous Injection:

a. Intermittent bolus: 50 mg (2 mL) every 6 to 8 hours. Dilute GEPIN Injection, 50 mg, in 0.9% sodium chloride injection or other compatible IV solution to a concentration no greater than 2.5 mg/mL (20 mL). Inject at a rate no greater than 4 mL/min (5 minutes).

b. Intermittent infusion: 50 mg (2 mL) every 6 to 8 hours. Dilute GEPIN Injection, 50 mg, in 5% dextrose injection or other compatible IV solution to a concentration no greater than 0.5 mg/mL (100 mL). Infuse at a rate no greater than 5 to 7 mL/min (15 to 20 minutes).

Continuous Intravenous Infusion:

Add GEPIN Injection to 5% dextrose injection or other compatible IV solution. Deliver at a rate of 6.25 mg/hour (e.g., 150 mg [6 mL] of GEPIN Injection in 250 mL of 5% dextrose injection at 10.7 mL/hour).

Children:

Safety and effectiveness of Gepin injection have not been established in case of children.

Contraindications

It is contraindicated for patients with known hypersensitivity to the drug or any of its ingredients.

Side Effects

Ranitidine may cause reversible confusion, headache, malaise, constipation, diarrhea, increase SGPT, hepatitis, anaphylactoid reactions, thrombocytopenia and leucopenia. It may also cause rarely tachycardia, bradycardia, atrioventricular block and premature ventricular beats.

Precautions

The doses should be reduced in patients with impaired renal function. Caution should be taken in patients hepatic dysfunction. It should be avoided in patients with a history of acute porphyria.

Drug Interactions

Recommended dose of Ranitidine do not inhibit the action of the Cytochrome P-450 linked oxygenase enzymes in the liver. (Dose of Ranitidine up to 400 mg per day causes no interaction and it has no effect on warfarin clearance or prothrombin time.)

Use in Pregnancy and Lactation

It should be used during pregnancy category only if clearly indicated. As Ranitidine is secreted in human milk, caution should be exercised when it is administered to a nursing mother.

Storage Conditions

Store between 4°C and 25°C. Protect from light and keep away from children.

Commercial Pack

Gepin Tablet: Each box contains 10 blister packs of 10 Tablets.
Gepin Syrup 100 ml : Each bottle contains 100 ml syrup.
Gepin Syrup 200 ml : Each bottle contains 200 ml syrup.
Gepin IM/IV Injection: Each box contains 2 blister packs of 5 ampoules of 2 ml sterile solution.

Manufactured by :

general **GENERAL**
Pharmaceuticals Ltd.
Gazipur, Bangladesh